Clinical, Behavioral, and Psychosocial Outcomes of Tumor Molecular Profiling in Children, Adolescents, and Young Adults Treated for Cancer Read more
A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants with Advanced Solid Tumors Read more
DAREONTM-7: A Phase I, open-label, dose escalation and expansion trial to investigate safety and tolerability of BI 764532 intravenous infusions in combination with standard of care (platinum and etoposide) in first-line treatment of patients with neuroendocrine carcinomas (NEC) Read more
A Phase 1/2a, Multicenter, Open-label Study of BMS-986490 with or without Bevacizumab in Advanced Solid Tumors Read more
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab Read more
A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) combinations in Adult Participants with Advanced Solid Tumors Read more
A Phase 1b Study of Gilteritinib in Participants with Locally Advanced or Metastatic NSCLC with ALK Rearrangement After Prior Treatment with an ALK Inhibitor Read more
A Phase 1a/1b Study of 27T51, an anti-MUC16 CAR T cell drug product administered alone or in combination for participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer Read more
